|
Age (years old)
|
56 (24–78)
|
|
Tumor size (mm)
|
28.7 (9.2–119.8)
|
|
Skin infiltration Negative / Positive
|
318 (84.1%) / 60 (15.9%)
|
|
Lymph node metastasis N0 / N1 / N2 / N3
|
132 (34.9%) / 140 (37.0%) / 71 (18.8%) / 35 (9.3%)
|
|
Estrogen receptor Negative / Positive
|
223 (59.0%) / 155 (41.0%)
|
|
Progesterone receptor Negative / Positive
|
301 (79.6%) / 77 (20.4%)
|
|
HER2 Negative / Positive
|
238 (63.0%) / 140 (37.0%)
|
|
Ki67 ≤ 14% / > 14%
|
121 (32.0%) / 257 (68.0%)
|
|
Intrinsic subtype HRBC / HER2BC / TNBC
|
159 (42.1%) / 93 (24.6%) / 126 (33.3%)
|
|
Objective response rate Non-Responders / Responders
|
41 (10.8%) / 337 (89.2%)
|
|
Pathological response Non-pCR / pCR
|
250 (66.1%) / 128 (33.9%)
|
|
TILs Low / High
|
209 (55.3%) / 169 (44.7%)
|
|
Body mass index (kg/m2)
|
21.9 (14.3–38.5)
|
|
Body mass index categorized Underweight / Normal / Overweight / Obese
|
49 (13.0%) / 244 (64.5%) / 66 (17.5%) / 19 (5.0%)
|
